Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives

Cangrelor is the only currently available intravenous platelet P2Y(12) receptor inhibitor. It is characterized by potent, predictable, and rapidly reversible antiplatelet effects. Cangrelor has been tested in the large CHAMPION (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Plat...

Descripción completa

Detalles Bibliográficos
Autores principales: De Luca, Leonardo, Steg, Philippe Gabriel, Bhatt, Deepak L., Capodanno, Davide, Angiolillo, Dominick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Contemporary Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403274/
https://www.ncbi.nlm.nih.gov/pubmed/34212768
http://dx.doi.org/10.1161/JAHA.121.022125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403274/
https://www.ncbi.nlm.nih.gov/pubmed/34212768
http://dx.doi.org/10.1161/JAHA.121.022125

Ejemplares similares